WO2002040512A3 - Human beta-defensin-3 - Google Patents

Human beta-defensin-3 Download PDF

Info

Publication number
WO2002040512A3
WO2002040512A3 PCT/EP2001/013174 EP0113174W WO0240512A3 WO 2002040512 A3 WO2002040512 A3 WO 2002040512A3 EP 0113174 W EP0113174 W EP 0113174W WO 0240512 A3 WO0240512 A3 WO 0240512A3
Authority
WO
WIPO (PCT)
Prior art keywords
defensin
human beta
inventive peptides
treat
treating
Prior art date
Application number
PCT/EP2001/013174
Other languages
German (de)
French (fr)
Other versions
WO2002040512A2 (en
Inventor
Wolf-Georg Forssmann
Enno Kluever
Jose-Ramon Conejo-Garcia
Knut Adermann
Robert Bals
Hans-Juergen Maegert
Original Assignee
Ipf Pharmaceuticals Gmbh
Wolf-Georg Forssmann
Enno Kluever
Jose-Ramon Conejo-Garcia
Knut Adermann
Robert Bals
Hans-Juergen Maegert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipf Pharmaceuticals Gmbh, Wolf-Georg Forssmann, Enno Kluever, Jose-Ramon Conejo-Garcia, Knut Adermann, Robert Bals, Hans-Juergen Maegert filed Critical Ipf Pharmaceuticals Gmbh
Priority to AU2002227925A priority Critical patent/AU2002227925A1/en
Publication of WO2002040512A2 publication Critical patent/WO2002040512A2/en
Publication of WO2002040512A3 publication Critical patent/WO2002040512A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a peptide, hBD-3 (human beta-defensin-3) and to derivatives and fragments thereof, in addition to a method for producing the same. The inventive peptides can be made available as medicaments and can be used to resist and combat pathogenic germs. They are particularly useful for treating bacterial diseases of the respiratory system, in particular for infections caused by Burkholderia cepacia and Pseudomonas aeroginosa and for treating cystic fibrosis. The inventive peptides can also be used to treat inflammatory diseases of the gastro-intestinal tract, urogenital tract and to treat septicaemia.
PCT/EP2001/013174 2000-11-14 2001-11-14 Human beta-defensin-3 WO2002040512A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002227925A AU2002227925A1 (en) 2000-11-14 2001-11-14 Human beta-defensin-3

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10056365.1 2000-11-14
DE10056365 2000-11-14
DE10116220.0 2001-03-30
DE10116220 2001-03-30

Publications (2)

Publication Number Publication Date
WO2002040512A2 WO2002040512A2 (en) 2002-05-23
WO2002040512A3 true WO2002040512A3 (en) 2002-12-19

Family

ID=26007661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/013174 WO2002040512A2 (en) 2000-11-14 2001-11-14 Human beta-defensin-3

Country Status (2)

Country Link
AU (1) AU2002227925A1 (en)
WO (1) WO2002040512A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
EP2010561A4 (en) * 2006-04-27 2010-03-24 Singapore Health Services Pte Antimicrobial peptides
EP2396023A2 (en) * 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
KR101320472B1 (en) * 2010-06-16 2013-10-23 주식회사 나이벡 Antibacterial or Anti-inflammatory Peptides and Pharmaceutical Composition Containing Thereof
CN102533857B (en) * 2012-02-21 2014-05-07 西北农林科技大学 HBD3 tracheal epithelium specificity expression vector and recombinant cell constructed from same
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
AU2014234314B2 (en) 2013-03-21 2018-02-15 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
ES2710973T3 (en) * 2014-08-29 2019-04-29 Ceinge Biotecnologie Avanzate S C A R L Analogs of cyclic beta defensins for the treatment of infections
KR101693533B1 (en) 2015-03-26 2017-01-06 서울대학교산학협력단 Anti-Cancer Peptide for Inhibition of Proliferation on the Cancer Stem Cells and Use Thereof
KR102244161B1 (en) * 2018-08-31 2021-04-26 주식회사 나이벡 Use of Peptides having Ability to inhibit multiple disease biomarkers' expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013080A1 (en) * 1997-09-10 1999-03-18 Zymogenetics, Inc. Beta-defensins
WO2000046245A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Human antibiotic proteins
WO2001092309A2 (en) * 2000-06-01 2001-12-06 University Of Iowa Research Foundation Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
WO2002004487A2 (en) * 2000-07-11 2002-01-17 Ipf Pharmaceuticals Gmbh Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses
WO2002009738A1 (en) * 2000-07-28 2002-02-07 Murphy Christopher J Transplant media

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013080A1 (en) * 1997-09-10 1999-03-18 Zymogenetics, Inc. Beta-defensins
WO2000046245A2 (en) * 1999-02-01 2000-08-10 Schering Aktiengesellschaft Human antibiotic proteins
WO2001092309A2 (en) * 2000-06-01 2001-12-06 University Of Iowa Research Foundation Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide
WO2002004487A2 (en) * 2000-07-11 2002-01-17 Ipf Pharmaceuticals Gmbh Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses
WO2002009738A1 (en) * 2000-07-28 2002-02-07 Murphy Christopher J Transplant media

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDREU D ET AL: "Animal antimicrobial peptides: an overview.", BIOPOLYMERS. UNITED STATES 1998, vol. 47, no. 6, 1998, pages 415 - 433, XP000996625, ISSN: 0006-3525 *
COLE A M ET AL: "Human antimicrobial peptides: analysis and application.", BIOTECHNIQUES. UNITED STATES OCT 2000, vol. 29, no. 4, October 2000 (2000-10-01), pages 822 - 826, 828, 830 - 831, XP001093806, ISSN: 0736-6205 *
DATABASE EBI [online] 21 September 2000 (2000-09-21), CHRISTOPHERS, E. ET AL.: "Human antibiotic protein", XP002209339, retrieved from EBI Database accession no. AX033352 *
DATABASE EBI [online] 6 July 1999 (1999-07-06), ADLER, D. ET AL.: "New zamp1 polypeptide and polynucleotide, human beta-defensins - useful as diagnostic reagents and for treatment of microbial infections, and AIDS", XP002209338, retrieved from EBI Database accession no. AAY07243 *
GARCÍA J R ET AL: "Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction.", CELL AND TISSUE RESEARCH. GERMANY NOV 2001, vol. 306, no. 2, November 2001 (2001-11-01), pages 257 - 264, XP002206910, ISSN: 0302-766X *
HARDER J ET AL: "Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 23 FEB 2001, vol. 276, no. 8, 23 February 2001 (2001-02-23), pages 5707 - 5713, XP002206911, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2002227925A1 (en) 2002-05-27
WO2002040512A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
NO20072906L (en) Method of preventing or treating respiratory infections and acute otitis media in children
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
GB0031088D0 (en) Medicaments
WO2001082971A3 (en) Cyclodextrin containing glycopeptide antibiotic compositions
NO954996L (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
WO2003010138A3 (en) Piperidine derivatives as antibacterial agents
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
WO2003049685A3 (en) Treatment for age-related macular degeneration
WO2002040512A3 (en) Human beta-defensin-3
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
AU1794601A (en) Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
WO2002056833A3 (en) Preparation of a therapeutic composition
TW200510449A (en) Acylated nonadepsipeptides
EP1057828A3 (en) Trovafloxacin oral suspensions
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
WO2006009525A3 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
WO2000058475A3 (en) Streptococcus pneumoniae antigens
WO2005118613A3 (en) Antibacterial amide macrocycles
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
YU8804A (en) Single dose azithromycin
WO2003008564A3 (en) Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP